Catalog No.
DHC12504
Description
Aducanumab (brand name: Aduhelm) is an amyloid beta-directed monoclonal antibody that targets amyloid beta in the brains of people with Alzheimer’s to reduce its buildup. Aducanumab is a monoclonal antibody (a protein that helps your immune system target other proteins), and it is designed to help your body remove something called amyloid beta from the brain. Amyloid beta is an important protein involved in the progression of Alzheimer’s disease. Aducanumab is given intravenously (infused through a vein) monthly. Aducanumab does not cure Alzheimer’s disease, but one (of two) large clinical studies suggests that aducanumab may slow the progression of the earliest symptoms of Alzheimer’s disease.
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
AICD-57, A4, Beta-CTF, Protease nexin-II, Gamma-CTF(50), ABPP, S-APP-beta, APP, Abeta40, Abeta42, AID(59), Amyloid intracellular domain 59, AID(57), S-APP-alpha, Gamma-CTF(59), Beta-secretase C-terminal fragment, Amyloid-beta precursor protein, Amyloid precursor protein, Beta-APP42, PreA4, Alzheimer disease amyloid protein, APPI, PN-II, AICD-59, Alpha-secretase C-terminal fragment, Amyloid-beta A4 protein, Amyloid intracellular domain 57, CVAP, Amyloid intracellular domain 50, Beta-APP40, AD1, Cerebral vascular amyloid peptide, AID(50), Alpha-CTF, Gamma-CTF(57), AICD-50
Concentration
2.3 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P05067
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
BART, BIIB-037, CAS: 1384260-65-4
Clone ID
Aducanumab
A resurrection of aducanumab for Alzheimer's disease, PMID: 31978357
Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019, PMID: 33135381
Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval, PMID: 32787971
First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease, PMID: 29067304
The antibody aducanumab reduces Aβ plaques in Alzheimer's disease, PMID: 27582220
Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β, PMID: 29686315
Aducanumab and the FDA - where are we now?, PMID: 33442064
Aducanumab reduces Aβ plaques in Alzheimer's disease, PMID: 27739124
Alzheimer disease and aducanumab: adjusting our approach, PMID: 31138932
Questions EMERGE as Biogen claims aducanumab turnaround, PMID: 31784690
Drug treatments in Alzheimer's disease, PMID: 27251914
Impact of Reference and Target Region Selection on Amyloid PET SUV Ratios in the Phase 1b PRIME Study of Aducanumab, PMID: 29777003
Clinical Development of Aducanumab, an Anti-Aβ Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease, PMID: 29181491
Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice, PMID: 27810931
Post-hoc analysis could give new life to the Alzheimer's drug aducanumab, PMID: 33139929
Open Peer Commentary to "Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE Trials as reported by Biogen December 2019", PMID: 33135288
Addendum: The antibody aducanumab reduces Aβ plaques in Alzheimer's disease, PMID: 28640269
Alzheimer's disease: Recent treatment strategies, PMID: 32941929
Symptomatic amyloid-related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab, PMID: 33072846
Anti-Aβ Antibody Aducanumab Regulates the Proteome of Senile Plaques and Closely Surrounding Tissue in a Transgenic Mouse Model of Alzheimer's Disease, PMID: 33252074
Antibodies to watch in 2020, PMID: 31847708
The amyloid hypothesis of Alzheimer's disease at 25 years, PMID: 27025652
Aducanumab, PMID: 34424635
Aducanumab: First Approval, PMID: 34324167
Aducanumab, PMID: 34251780
Aducanumab-avwa, PMID: 34268554
From monomer to fibril: Abeta-amyloid binding to Aducanumab antibody studied by molecular dynamics simulation, PMID: 32666627
A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease, PMID: 30610216
Aducanumab: What about the Patient?, PMID: 34322904
Alzheimer's disease: targeting the glutamatergic system, PMID: 32048098
Drug candidates in clinical trials for Alzheimer's disease, PMID: 28720101
Aducanumab for Alzheimer's disease?, PMID: 34226181
Why aducanumab is important, PMID: 34413516
Anti-amyloid-β protein agents for the treatment of Alzheimer's disease: an update on emerging drugs, PMID: 32772738
Kinetic fingerprints differentiate the mechanisms of action of anti-Aβ antibodies, PMID: 32989305
Aducanumab and the certainty of evidence, PMID: 34405228
Pathways Connecting Late-Life Depression and Dementia, PMID: 32231570
Efficacy and safety of anti-amyloid- β immunotherapy for Alzheimer's disease: a systematic review and network meta-analysis, PMID: 29296624
Passive antiamyloid immunotherapy for Alzheimer's disease, PMID: 32040044
The next steps in curing Alzheimer's disease, PMID: 31699316
Lessons Learnt from the Second Generation of Anti-Amyloid Monoclonal Antibodies Clinical Trials, PMID: 33321511
AMDA Position Statement on Aducanumab, PMID: 34456010
The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis, PMID: 31706733
Acute targeting of pre-amyloid seeds in transgenic mice reduces Alzheimer-like pathology later in life, PMID: 33199898
Aducanumab: Appropriate use recommendations, PMID: 34314093
[Aducanumab and Alzheimer's disease: a critical reflection], PMID: 34263875
Aducanumab: look before leaping, PMID: 34413517
Aducanumab, amyloid, and culture wars, PMID: 34413026
The Problem of Aducanumab for the Treatment of Alzheimer Disease, PMID: 34138642
Aducanumab: The first targeted Alzheimer's therapy, PMID: 34234067
For research use only. Not for human or drug use.
